MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 558379 | Name: SR-2211
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SR-2211 is a synthetic RORγ-selective modulator that potently inhibits the production of IL-17 in cells. Treatment of Th17 cells with SR-2211 suppressed the expression and production of inflammatory cytokines. SR-2211 reduced inflammatory cytokine production in LPS-stimulated RAW 264.7 cells. Mice with CIA that received SR-2211 twice daily for 15 days exhibited a statistically significant reduction in joint inflammation as compared to mice that received only vehicle. Interestingly, systemic Th1 cell activation was detected in SR-2211-treated mice with CIA, as indicated by an increase in interferon-γ levels.

Chemical Structure

SR-2211
SR-2211
CAS#1359164-11-6

Theoretical Analysis

MedKoo Cat#: 558379

Name: SR-2211

CAS#: 1359164-11-6

Chemical Formula: C26H24F7N3O

Exact Mass: 527.1808

Molecular Weight: 527.49

Elemental Analysis: C, 59.20; H, 4.59; F, 25.21; N, 7.97; O, 3.03

Price and Availability

Size Price Availability Quantity
5mg USD 350.00 2 Weeks
10mg USD 550.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
SR-2211; SR2211;SR 2211;
IUPAC/Chemical Name
2-fluoro-4'-[[4-(4-pyridinylmethyl)-1-piperazinyl]methyl]-aa-bis(trifluoromethyl)-[1,1'-biphenyl]-4-methanol
InChi Key
KVHKWAZUPPBMLL-UHFFFAOYSA-N
InChi Code
InChI=1S/C26H24F7N3O/c27-23-15-21(24(37,25(28,29)30)26(31,32)33)5-6-22(23)20-3-1-18(2-4-20)16-35-11-13-36(14-12-35)17-19-7-9-34-10-8-19/h1-10,15,37H,11-14,16-17H2
SMILES Code
OC(C(F)(F)F)(C(F)(F)F)C1=CC=C(C2=CC=C(CN3CCN(CC4=CC=NC=C4)CC3)C=C2)C(F)=C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, DMF, and ethanol
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
SR-2211 selectively binds RORγ (Ki = 105 nM), acting as an inverse agonist of constitutive in vitro RORγ activity (IC50 = 320 nM). It has minimal effects on RORα, LXRα, and FXR activities.
In vitro activity:
This article describes SR-2211, a selective RORγ modulator that potently inhibited the production of IL-17 in cells. Reference: ACS Chem Biol. 2012 Apr 20;7(4):672-7. https://pubmed.ncbi.nlm.nih.gov/22292739/
In vivo activity:
SR-2211 has potential utility for the treatment of inflammatory disease. Mice with collagen-induced arthritis (CIA) that received SR2211 had a statistically significant reduction in joint inflammation, compared to mice that received only vehicle treatment. Systemic Th1 cell activation was detected in SR-2211-treated mice with CIA. Reference: Arthritis Rheumatol. 2014 Mar;66(3):579-88. https://pubmed.ncbi.nlm.nih.gov/24574218/
Solvent mg/mL mM comments
Solubility
DMF 20.0 37.92
DMSO 20.0 37.92
Ethanol 10.0 18.96
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 527.49 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Kumar N, Lyda B, Chang MR, Lauer JL, Solt LA, Burris TP, Kamenecka TM, Griffin PR. Identification of SR2211: a potent synthetic RORγ-selective modulator. ACS Chem Biol. 2012 Apr 20;7(4):672-7. doi: 10.1021/cb200496y. Epub 2012 Feb 13. PMID: 22292739; PMCID: PMC3331898. 2. Chang MR, Lyda B, Kamenecka TM, Griffin PR. Pharmacologic repression of retinoic acid receptor-related orphan nuclear receptor γ is therapeutic in the collagen-induced arthritis experimental model. Arthritis Rheumatol. 2014 Mar;66(3):579-88. doi: 10.1002/art.38272. PMID: 24574218; PMCID: PMC4474185.
In vitro protocol:
1. Kumar N, Lyda B, Chang MR, Lauer JL, Solt LA, Burris TP, Kamenecka TM, Griffin PR. Identification of SR2211: a potent synthetic RORγ-selective modulator. ACS Chem Biol. 2012 Apr 20;7(4):672-7. doi: 10.1021/cb200496y. Epub 2012 Feb 13. PMID: 22292739; PMCID: PMC3331898.
In vivo protocol:
1. Chang MR, Lyda B, Kamenecka TM, Griffin PR. Pharmacologic repression of retinoic acid receptor-related orphan nuclear receptor γ is therapeutic in the collagen-induced arthritis experimental model. Arthritis Rheumatol. 2014 Mar;66(3):579-88. doi: 10.1002/art.38272. PMID: 24574218; PMCID: PMC4474185.
1: Li W, Berlinicke C, Huang Y, Giera S, McGrath AG, Fang W, Chen C, Takaesu F, Chang X, Duan Y, Kumar D, Chang C, Mao HQ, Sheng G, Dodge JC, Ji H, Madden S, Zack DJ, Chamling X. High-throughput screening for myelination promoting compounds using human stem cell-derived oligodendrocyte progenitor cells. iScience. 2023 Feb 8;26(3):106156. doi: 10.1016/j.isci.2023.106156. PMID: 36852281; PMCID: PMC9958491. 2: Kumar N, Lyda B, Chang MR, Lauer JL, Solt LA, Burris TP, Kamenecka TM, Griffin PR. Identification of SR2211: a potent synthetic RORγ-selective modulator. ACS Chem Biol. 2012 Apr 20;7(4):672-7. doi: 10.1021/cb200496y. Epub 2012 Feb 13. PMID: 22292739; PMCID: PMC3331898. 3: Chang MR, Lyda B, Kamenecka TM, Griffin PR. Pharmacologic repression of retinoic acid receptor-related orphan nuclear receptor γ is therapeutic in the collagen-induced arthritis experimental model. Arthritis Rheumatol. 2014 Mar;66(3):579-88. doi: 10.1002/art.38272. PMID: 24574218; PMCID: PMC4474185. 4: Morioka N, Tsuruta M, Masuda N, Yamano K, Nakano M, Kochi T, Nakamura Y, Hisaoka-Nakashima K. Inhibition of Nuclear Receptor Related Orphan Receptor γ Ameliorates Mechanical Hypersensitivity Through the Suppression of Spinal Microglial Activation. Neuroscience. 2023 Aug 21;526:223-236. doi: 10.1016/j.neuroscience.2023.07.002. Epub 2023 Jul 5. PMID: 37419402. 5: Mei C, Wang X, Meng F, Zhang X, Chen L, Yan S, Xue J, Sun X, Wang Y. Aucuboside Inhibits the Generation of Th17 Cells in Mice Colitis. Front Pharmacol. 2021 Jul 16;12:696599. doi: 10.3389/fphar.2021.696599. PMID: 34335262; PMCID: PMC8322701. 6: Gao M, Guo L, Wang H, Huang J, Han F, Xiang S, Wang J. Orphan nuclear receptor RORγ confers doxorubicin resistance in prostate cancer. Cell Biol Int. 2020 Oct;44(10):2170-2176. doi: 10.1002/cbin.11411. Epub 2020 Jul 7. PMID: 32584473. 7: Toporova L, Grimaldi M, Boulahtouf A, Balaguer P. Assessing the Selectivity of FXR, LXRs, CAR, and RORγ Pharmaceutical Ligands With Reporter Cell Lines. Front Pharmacol. 2020 Jul 24;11:1122. doi: 10.3389/fphar.2020.01122. PMID: 32792956; PMCID: PMC7394005. 8: Zou H, Yang Y, Shi Z, Wu X, Liu R, Yu AM, Chen HW. Nuclear receptor RORγ inverse agonists/antagonists display tissue- and gene-context selectivity through distinct activities in altering chromatin accessibility and master regulator SREBP2 occupancy. Pharmacol Res. 2022 Aug;182:106324. doi: 10.1016/j.phrs.2022.106324. Epub 2022 Jun 21. PMID: 35750301; PMCID: PMC10158160. 9: Lin H, Song P, Zhao Y, Xue LJ, Liu Y, Chu CQ. Targeting Th17 Cells with Small Molecules and Small Interference RNA. Mediators Inflamm. 2015;2015:290657. doi: 10.1155/2015/290657. Epub 2015 Dec 17. PMID: 26792955; PMCID: PMC4697089. 10: Stone L. Prostate cancer: ROR-γ drives androgen receptor expression. Nat Rev Urol. 2016 May;13(5):237. doi: 10.1038/nrurol.2016.71. Epub 2016 Apr 13. PMID: 27071453. 11: Chang MR, Ciesla A, Strutzenberg TS, Novick SJ, He Y, Garcia-Ordonez RD, Frkic RL, Bruning JB, Kamenecka TM, Griffin PR. Unique Polypharmacology Nuclear Receptor Modulator Blocks Inflammatory Signaling Pathways. ACS Chem Biol. 2019 May 17;14(5):1051-1062. doi: 10.1021/acschembio.9b00236. Epub 2019 Apr 15. PMID: 30951276. 12: Oh TG, Wang SM, Acharya BR, Goode JM, Graham JD, Clarke CL, Yap AS, Muscat GEO. The Nuclear Receptor, RORγ, Regulates Pathways Necessary for Breast Cancer Metastasis. EBioMedicine. 2016 Apr;6:59-72. doi: 10.1016/j.ebiom.2016.02.028. Epub 2016 Feb 18. PMID: 27211549; PMCID: PMC4856749. 13: Wang J, Zou JX, Xue X, Cai D, Zhang Y, Duan Z, Xiang Q, Yang JC, Louie MC, Borowsky AD, Gao AC, Evans CP, Lam KS, Xu J, Kung HJ, Evans RM, Xu Y, Chen HW. ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer. Nat Med. 2016 May;22(5):488-96. doi: 10.1038/nm.4070. Epub 2016 Mar 28. Erratum in: Nat Med. 2016 Jun 7;22(6):692. PMID: 27019329; PMCID: PMC5030109. 14: Melton AC, Melrose J, Alajoki L, Privat S, Cho H, Brown N, Plavec AM, Nguyen D, Johnston ED, Yang J, Polokoff MA, Plavec I, Berg EL, O'Mahony A. Regulation of IL-17A production is distinct from IL-17F in a primary human cell co-culture model of T cell-mediated B cell activation. PLoS One. 2013;8(3):e58966. doi: 10.1371/journal.pone.0058966. Epub 2013 Mar 7. PMID: 23505568; PMCID: PMC3591360.